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Abstract
This study aimed at identifying clinical factors for predicting hematologic toxicity after
radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab in clinical practice.
Methods—Hematologic data were available from 14 non-Hodgkin lymphoma patients treated
with 90Y-ibritumomab tiuxetan and 18 who received 131I-tositumomab. The percentage baseline at
nadir and 4 wk post nadir and the time to nadir were selected as the toxicity indicators for both
platelets and neutrophils. Multiple linear regression analysis was performed to identify significant
predictors (P < 0.05) of each indicator.
Results—For both platelets and neutrophils, pooled and separate analyses of 90Y-ibritumomab
tiuxetan and 131I-tositumomab data yielded the time elapsed since the last chemotherapy as the
only significant predictor of the percentage baseline at nadir. The extent of bone marrow
involvement was not a significant factor in this study, possibly because of the short time elapsed
since the last chemotherapy of the 7 patients with bone marrow involvement. Because both
treatments were designed to deliver a comparable bone marrow dose, this factor also was not
significant. None of the 14 factors considered was predictive of the time to nadir. The R2 value for
the model predicting percentage baseline at nadir was 0.60 for platelets and 0.40 for neutrophils.
This model predicted the platelet and neutrophil toxicity grade to within ±1 for 28 and 30 of the 32
patients, respectively. For the 7 patients predicted with grade I thrombocytopenia, 6 of whom had
actual grade I–II, dosing might be increased to improve treatment efficacy.
Conclusion—The elapsed time since the last chemotherapy can be used to predict hematologic
toxicity and customize the current dosing method in radioimmunotherapy.
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The radioimmunoconjugates 90Y-ibritumomab tiuxetan (Zevalin; Spectrum
Pharmaceuticals, Inc.) and 131I-tositumomab (Bexxar; GlaxoSmithKline) are currently
approved by the U.S. Food and Drug Administration for non-Hodgkin lymphoma treatment.
Both conjugates have comparable efficacy and toxicity profiles (1–7). The major toxicities
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have been transient thrombocytopenia and neutropenia. These toxicities are mainly caused
by radiation that damages the bone marrow. In radioimmunotherapy, the absorbed dose
delivered to the bone marrow is relatively high because of the long clearance time of the
radiolabeled antibodies in the blood. The activity that can be safely administered to patients
is therefore limited by the bone marrow dose (BMD).
In addition to the BMD, hematologic toxicity after radioimmunotherapy also has been
associated with the treatment history of patients and variable marrow reserve.
Radioimmunotherapy patients have frequently undergone other therapies that may have
damaged a large fraction of their bone marrow reserve (8). For patients treated with 90Y-
ibritumomab tiuxetan, baseline platelet counts, extent of bone marrow involvement, and
number of prior chemotherapy regimens were identified as significant predictors of
hematologic toxicity, whereas BMD was not (9). These results indicate that individual
response to radiation may vary largely because of inherent interpatient differences.
Predicting hematologic toxicity on a patient-specific basis is therefore crucial in optimizing
treatment and avoiding complications in radioimmunotherapy. Presently, baseline platelet
count is the only factor considered when deciding between a standard and an attenuated dose
regimen, for both 90Y-ibritumomab tiuxetan and 131I-tositumomab (1). Indeed, baseline
platelet count is considered as a surrogate for bone marrow damage from prior therapies and
bone marrow involvement.
In this study, multiple linear regression analyses were performed to identify clinical factors
that could be used to predict hematologic toxicity after radioimmunotherapy with 90Y-
ibritumomab tiuxetan or 131I-tositumomab administered in clinical practice. Furthermore, if
knowledge of certain clinical factors enables identification of patients at low risk for
toxicity, the prescribed dosing could be increased, potentially leading to a greater treatment
benefit.
MATERIALS AND METHODS
Study Design and Patient Population
Thirty-eight chemotherapy-refractory non-Hodgkin lymphoma patients treated with 90Y-
ibritumomab tiuxetan (n = 20) or 131I-tositumomab (n = 18) were described in a previous
study that compared the response rate and hematologic toxicities of both agents (10). A
subset of 32 patients was considered for the present analysis because 6 patients treated
with 90Y-ibritumomab tiuxetan had only partial hematologic toxicity data available. Both
radioimmunotherapy agents are used routinely at our institution, and the choice of agent was
based on patient and disease characteristics, referring physician preference and familiarity,
and radiation safety issues. The 14 patient characteristics recorded at the time of
radioimmunotherapy and considered as potential predictors of hematologic toxicity are
given in Table 1.
Absorbed Dose to Bone Marrow
The dosing guidelines for 90Y-ibritumomab tiuxetan and 131I-tositumomab require an
adjustment based on platelet counts. The standard activity level is recommended only for
patients with a platelet count of at least 150,000/mm3; patients with a platelet count of
100,000–149,000/mm3 receive less administered activity (4,5). In addition to the baseline
platelet count, dosing for 90Y-ibritumomab tiuxetan is based on the patient’s body weight.
Nine patients received the standard activity level (14.8 MBq/kg [0.4 mCi/kg]), and 5
patients received the reduced level (11.1 MBq/kg [0.3 mCi/kg]). The BMD was
approximated by multiplying the actual activity administered to the patient by the median
absorbed dose per unit activity of 1.3 mGy/MBq reported in the 90Y-ibritumomab tiuxetan
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package insert (11). In a recent MIRD report (12), a higher median BMD of 2.4 mGy/MBq
was reported. Both values were obtained using imaging-based marrow dosimetry. Estimates
of BMD with the blood-based model were not considered, because this approach does not
account for direct targeting of non-Hodgkin lymphoma within the bone marrow (13).
The therapeutic administered activity for 131I-tositumomab is determined by a
pretherapeutic dosimetry used to verify clearance kinetics in each patient and thereby the
activity required to deliver a total-body absorbed dose of 0.75 (platelet count ≥ 150,000/
mm3) or 0.65 Gy (platelet count within 100,000–149,000/mm3) (14,15). Twelve patients
received a full total-body dose of 0.75 Gy. Six patients received attenuated doses of 0.65 Gy
(n = 3), 0.60 Gy (n = 1), 0.55 Gy (n = 1), and 0.45 Gy (n = 1). Estimates of BMD were
derived from the total-body dose using a conversion factor of 2.7 given by the ratio of the
median BMD (0.65 mGy/MBq) to the median total-body dose (0.24 mGy/MBq) obtained
from the 131I-tositumomab package insert (16). A factor of 2.0 may be derived from the
study of O’Donoghue et al. (17) using various 131I-labeled antibodies; similarly, a factor of
2.1 may be deduced from a dosimetry study with 131I-rituximab (18).
Hematologic Toxicity Assessment
Platelet counts and absolute neutrophil counts (ANCs) were measured before therapy as a
baseline and then weekly for about 12 wk after radioimmunotherapy for all patients (n = 32).
Both the percentage of the baseline cell counts at nadir (PBN) and the time to nadir (TTN)
were used as indicators of toxicity. Additionally, the percentage of the baseline cell counts at
4 wk postnadir (PBP) was used to parameterize the recovery phase. Figures 1A and 1B plot
these parameters in relation to platelet counts and ANCs, respectively, normalized to
baseline for patient 25.
Statistical Analysis
Multiple linear regression analysis was performed for both outcome variables describing
hematologic toxicity (i.e., PBN and TTN) to assess the predictive value of the 14 potential
toxicity-related factors listed in Table 1. Platelets and neutrophils were treated separately.
The basic model equation takes the following form: Y = B0 + B1X1 + … + BnXn, where Y
corresponds to the outcome (dependent) variable, and Xis are the predictor (independent)
variables. B0 is the constant intercept, and B1…Bn are the regression coefficients. A
stepwise variable-selection procedure with entry and removal criteria of 0.05 and 0.10,
respectively, was used to include in the model only statistically significant predictors. The
measure used for statistical assessment of the model was a P value less than 0.05. The R2
value was examined to measure the goodness of fit. The test for multicolinearity was based
on the variance inflation factor. Statistical analyses were performed using the SPSS
statistical program (version 15.0; SPSS Inc.).
Practical Model for Clinical Application
The best resulting regression model was then used to predict absolute cell counts at nadir
(nadir count) of platelets and neutrophils by simply multiplying the predicted PBN by the
baseline cell counts at the time of radioimmunotherapy. The nadir counts of platelets and
neutrophils are the clinically important parameters with respect to the degree of hematologic
toxicity. However, considering PBN instead of nadir count for the statistical analysis
circumvents the evident dependence of baseline cell counts in the linear regression model. A
validation using the leave-1-out analysis was performed to assess our final regression model.
In other words, 1 patient was removed from the original set of 32. The predictors selected
for the final model and the data from the remaining 31 patients were used to fit a regression
equation. The resulting equation was then used to predict PBN and nadir count of the patient
who had been removed. This process was repeated for every patient so that the final model
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was tested 32 times. For further analysis, observed and predicted nadir counts were clustered
into toxicity grade representation. Grade I–IV thrombocytopenia and neutropenia were
determined using the Common Terminology Criteria for Adverse Events (version 3.0;
National Cancer Institute). Observed and predicted toxicity grades were compared with each
other using percentages of correct predictions and percentages of predictions within 1 grade
of deviation.
Modeling of Recovery Phase
Comparing PBN with PBP provides information about the degree of reversibility of
thrombocytopenia and neutropenia. Scatter plots were used to qualitatively determine
whether there was a correlation between both variables. Furthermore, PBP was
quantitatively related to PBN based on simple theoretic considerations. Cell population
recovery often exhibits nonexponential kinetics that can be described satisfactorily using a
logistic function. This model was used to characterize the recovery phase of white blood
cells after chemotherapy (19). Taking S(t) as the percentage of the baseline cell counts at
time t after the nadir, the specific growth rate of S(t), [dS(t)/dt]/S(t), decreases linearly with
an increase of S(t). Accordingly, the logistic recovery function may be expressed as:
Eq. 1
S0 denotes the initial value of S(t) in the recovery phase and Smax the asymptotic limit to
repopulation. The parameter λ is the maximal specific growth rate. In our study, S0 is
equivalent to PBN, and Smax is set to 100%, assuming that the baseline is the maximum-
achievable recovery value. According to Equation 1, the value of S(t) at 4 wk postnadir—
that is, PBP—may be expressed as:
Eq. 2
where a is set to e−λ×(28 d). Regression analysis was used to test if the model in Equation 2
was appropriate to describe the relationship between PBP and PBN.
RESULTS
In Table 1, continuous data are expressed as mean ± SD, and categoric data are presented as
counts and percentages. As reported previously by Jacene et al. (10), excepting for BMD,
those characteristics did not significantly differ between both patient groups treated either
with 90Y-ibritumomab tiuxetan or with 131I-tositumomab (P < 0.05, 2-tailed t test and 2-
tailed Fisher exact test). The mean BMD for patients treated with 90Y-ibritumomab tiuxetan
was 1.3 ± 0.2 Gy according to the information provided by Spectrum Pharmaceuticals, Inc.
(11), and 2.5 ± 0.4 Gy according to the study by Fisher et al. (12). Both values were
significantly different from the mean BMD of 1.9 ± 0.2 Gy obtained for 131I-tositumomab
patients (P < 0.001 for both estimates); however, the average of both values, 1.9 ± 0.3 Gy,
was perfectly compatible. For platelets, mean values of PBN, TTN, and PBP were 30% ±
25%, 37 ± 14 d, and 70% ± 34%, respectively, and for neutrophils, mean values were 33% ±
24%, 42 ± 14 d, and 89% ± 44%, respectively.
The multiple linear regression analysis of PBN showed that the elapsed time since the last
chemotherapy (TLC) was the only significant variable (P < 0.05) affecting PBN for both
platelets and neutrophils. The regression coefficients were B0 = 2.8 ± 4.9 and B1 = 3.02 ±
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0.45 for platelets and B0 = 11.9 ± 5.7 and B1 = 2.37 ± 0.43 for neutrophils. In both cases, the
P value associated with B1 was less than 0.001. The resulting 1-variable linear equation is
plotted in Figures 2A and 2B for platelets and neutrophils, respectively. The R2 value of the
model predicting PBN was 0.60 for platelets and 0.40 for neutrophils. Both models were
statistically significant (P < 0.001). No multicolinearity problem was detected using the
variance inflation factor test, meaning that none of the 14 factors examined was strongly
correlated with any of the other factors. Regarding TTN, none of the 14 factors considered
was predictive, and thus no regression model was available.
The linear regression of PBN on TLC was also performed separately for the 90Y-
ibritumomab tiuxetan and 131I-tositumomab groups. Results are shown in Figures 2C and
2D. The slopes between 90Y-ibritumomab tiuxetan and 131I-tositumomab were not
statistically different at the 0.05 significance level (Chow test).
Predicted counts at nadir resulting from the leave-1-out analysis are shown in Supplemental
Table 1 (supplemental materials are available online only at http://jnm.snmjournals.org) for
platelets and in Supplemental Table 2 for neutrophils. The model was able to predict platelet
counts at nadir within ±25,000/mm3 for 21 of 32 patients (66%) and ANC at nadir within
±500/mm3 for 19 of 32 patients (59%). The ability to predict toxicity grade at nadir is also
reported in Supplemental Tables 1 and 2. For platelets, an exact classification—that is, grade
I, II, III, or IV—was obtained for 16 of 32 patients (50%), and predicted toxicity grades
ranged within ±1 grade for 28 of 32 patients (88%). Regarding neutrophils, 13 of 32 patients
(41%) were predicted with the correct toxicity grade, and 30 of 32 patients (94%) were
predicted within ±1 toxicity grade.
Figure 3 shows the relationship between PBP and PBN. The function given in Equation 2
fits well with the platelet data using a nonlinear regression method (R2 = 0.51). However,
this model was not appropriate for neutrophils (R2 = 0.21).
DISCUSSION
Multiple linear regression analysis revealed TLC as the only significant variable affecting
PBN for both platelets and neutrophils. The increased toxicity for short TLC supports the
hypothesis that hematopoietic stem or progenitor cells are hyperproliferative and more
radiosensitive immediately after chemotherapy. Siegel et al. (20) showed that elevated levels
of the plasma FLT3-L, a stimulatory cytokine of hematopoiesis, may indicate increased
radiosensitivity of the bone marrow in patients receiving radioimmunotherapy. Moreover,
we found that short TLC was not correlated with a decrease of baseline blood cell counts at
the time of radioimmunotherapy; on the contrary, the correlation is somewhat negative (R =
−0.37, P < 0.05 for platelets; R = −0.11, P = 0.54 for neutrophils). In other words, baseline
platelet count and ANC were not lower for patients who underwent recent chemotherapy,
suggesting that they have recovered to their prior chemotherapy values. The increased
hematologic toxicity observed for low values of TLC may be related to an incomplete bone
marrow recovery after chemotherapy. As suggested by Juweid et al. (8), there is a time delay
between hematologic recovery and actual bone marrow recovery. In our toxicity-prediction
model, the TLC can be seen as a surrogate for the degree of bone marrow recovery from
prior chemotherapy.
Factors such as BMD, number of prior chemotherapy regimens, and, surprisingly, bone
marrow involvement were not statistically significant factors affecting hematologic toxicity
after radioimmunotherapy. The latter finding may reflect the dominant effect of the short
TLC on the 7 patients with bone marrow involvement. For comparison, Juweid et al. (8)
showed that BMD was the most important factor. However, their multivariate analysis was
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based on patients receiving a wide range of BMDs—that is, between 0.34 and 3.11 Gy.
BMDs delivered to patients in the present study ranged in a narrower interval (Table 1).
Treatments with 90Y-ibritumomab tiuxetan and 131I-tositumomab in the clinical setting were
designed to deliver a fixed BMD to each patient, to avoid high-grade toxicity. This may
explain why BMD was not a significant predictor of hematologic toxicity in our case.
Moreover, we were possibly able to identify TLC as a significant predictor because BMD
only weakly differed among patients. Nevertheless, as shown by Fisher et al. (12) for 90Y-
ibritumomab tiuxetan, estimates of BMD largely differ among studies, and accurate
dosimetry of bone marrow is challenging, even if individualized image-based approaches
are used (13).
Among patients treated with 90Y-ibritumomab tiuxetan, Wiseman et al. (9) found that
baseline platelet count, degree of bone marrow involvement, and number of prior therapies,
but not BMD, were accurate predictors of hematologic toxicity. Gregory et al. (21) reported
similar predictors of grade III–IV hematologic toxicity among patients treated with 131I-
tositumomab. In our study, 6 of 7 patients with bone marrow involvement showed a severe
hematologic toxicity, with a PBN below 30%. However, all 7 patients with bone marrow
involvement also had a relatively short TLC, ranging between 3 and 10 mo, which has been
shown with statistic significance (P < 0.001) to deplete platelets and neutrophils more
severely. Supplemental Figure 1 shows PBN for platelets and neutrophils and TLC for each
patient with respect to the presence of bone marrow involvement. On the basis of a Mann–
Whitney test, neither PBN for platelets and neutrophils nor TLC was significantly different
between groups both with and without bone marrow involvement (P = 0.05). A larger study
of patients with bone marrow involvement would be required to draw a conclusion about
these predictors. Similar to the finding of Juweid et al. (8), we found that the number of
prior chemotherapy regimens was not a significant predictor of hematologic toxicity, in
contrast to TLC.
One might expect that beyond a certain TLC this parameter would no longer predict PBN
because recovery would be complete. Figure 2 suggests no apparent threshold of TLC
within the 25-mo range of TLC values shown. According to Figure 3 and the logistic-based
model, patients with PBN of platelets above 20% reach more than 70% of baseline counts at
4 wk postnadir. This relationship between the PBN and PBP is of major importance for
defining the optimal time interval between cycles when designing trials of
radioimmunotherapy with multiple cycles (22). Such a relationship did not apply to ANC
recovery. The maximum specific growth rate λ was probably more patient-specific for ANC
than it was for platelets, particularly because 7 patients received granulocyte colony-
stimulating factor therapy. On the other hand, 6 patients treated with granulocyte colony-
stimulating factor had PBN below 20%, and the large variability of PBP above a PBN of
20% is not compatible with our simple model.
The toxicity-prediction model may be used to modify the current dosing method of
radioimmunotherapy by taking into account the TLC and baseline platelet counts. For this
purpose, we considered patients predicted with grade IV thrombocytopenia to be at high risk
of toxicity and those predicted with grade I thrombocytopenia to be at low risk of toxicity.
Six of the 7 patients predicted with grade IV had actual severe grade III–IV
thrombocytopenia, and 1 had grade II thrombocytopenia (patient 15). In the same way, 6 of
the 7 patients predicted with grade I had actual moderate grade I–II thrombocytopenia, and 1
had grade III thrombocytopenia (patient 18). Table 2 shows the patients predicted with grade
I or IV thrombocytopenia for whom we proposed reconsidering the dosing regimen. On the
basis of our predictions, the current low-dose regimen (L) would be proposed instead of the
current high-dose regimen (H) for 2 patients. In addition, a reduced low-dose regimen (L−)
would be suggested for 5 patients, to avoid severe toxicity (grade III or IV). Postponing the
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treatment (i.e., increasing TLC) could be an interesting alternative to avoid severe toxicity
without reducing the dosing. Conversely, the current high-dose regimen (H) would be
proposed instead of the current low-dose regimen (L) for 2 patients, and an increased high-
dose regimen (H+) would be suggested for 5 other patients, to potentially improve treatment
efficacy. In case of patient 18, applying an increased high-dose regimen (H+) would
aggravate the actual grade III thrombocytopenia. Nevertheless, with actual platelet count of
44,000/mm3 at nadir, it is highly improbable that this change produces life-threatening
toxicity. Ongoing data accumulation and analysis, as presented in this work, will be
important in assessing the clinical impact of the proposed L− and H+ dosing approach
regimens.
This study is limited by the small number of patients and needs to be expanded to a larger
population to determine the reproducibility of the coefficients used to predict hematologic
toxicity. Furthermore, the BMD estimates used have a high level of uncertainty. However,
the interpatient variability of BMD is probably sufficiently small for both
radiopharmaceuticals when used in the clinical setting and thus not likely to be a factor of
variability in hematologic toxicity. Finally, the model used to modify the current dosing
method does not consider tumor burden at the time of radioimmunotherapy. Clinically, for
patients with high tumor burden, it might not be appropriate to reduce the administered
activity to avoid reversible hematologic toxicity if this proposed dosing regimin jeopardizes
the treatment efficacy.
CONCLUSION
Hematologic toxicity was best predicted by TLC in this limited population of
radioimmunotherapy patients. This finding supports the hypothesis that hematopoietic stem
or progenitor cells are hyperproliferative and potentially more radiosensitive during the
recovery period after chemotherapy. Considering TLC in the adjustment of the
radioimmunotherapy dosing regimen may prevent overdosing, which could produce severe
hematologic toxicity and, conversely, avoid unnecessary underdosing, which could reduce
treatment efficacy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Measured platelet counts (A) and ANCs (B) for patient 25 treated with 90Y-ibritumomab
tiuxetan. All counts were normalized to baseline counts at beginning of
radioimmunotherapy. PLT = platelet; RIT = radioimmunotherapy.
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Linear regression of PBN on TLC for platelets (A) and neutrophils (B). (C and D) Results of
linear regression of PBN on TLC performed separately for 90Y-ibritumomab tiuxetan
and 131I-tositumomab groups. PLT = platelet.
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Relationship between PBP and PBN for platelets (A) and neutrophils (B) in whole
radioimmunotherapy patient population.
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TABLE 1
Fourteen Patient Characteristics (Variables) Considered as Potential Predictors of Hematologic Toxicity (32
Patients)
Variable Mean ± SD Range n
Age at radioimmunotherapy (y) 63 ± 10 40–80
Number of prior chemotherapy regimens at radioimmunotherapy (including rituximab) 3.1 ± 1.7 1–8
Time since last chemotherapy (mo) 8.9 ± 6.4 1–26
Bone marrow dose (Gy) 1.6 ± 0.4* 1.0–2.0*
2.1 ± 0.4† 1.2–2.8†
Baseline at time of radioimmunotherapy
    Platelets (103/mm3) 206 ± 100 67–535
    Absolute neutrophil count (1/mm3) 3,860 ± 1,880 1,530–11,080
Male sex 23 (72%)
Type of radioimmunotherapy agent
    90Y-ibritumomab tiuxetan 14 (44%)
    131I-tositumomab 18 (56%)
Disease stage at radioimmunotherapy
    I–II 5 (16%)
    III–IV 27 (84%)
Prior treatment with rituximab
    Alone 8 (25%)
    With chemotherapy 23 (72%)
Refractory to rituximab 14 (44%)
Bone marrow involvement at radioimmunotherapy 7 (22%)
History of prior bone marrow transplant 4 (13%)
History of prior radiation therapy 7 (22%)
History of prior treatment with fludarabine 9 (28%)
*
For patients treated with 90Y-ibritumomab tiuxetan, BMDs were obtained from BMD per unit activity reported in package insert provided by the
manufacturer (11).
†
For patients treated with 90Y-ibritumomab tiuxetan, BMDs were obtained from BMD per unit activity reported by Fisher et al. (12).
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TABLE 2
Patients Predicted with Thrombocytopenia Grade I or IV for Whom Dosing Regimens Were Reevaluated
According to Toxicity-Prediction Model
Dosing regimen
Patient no. Actual Proposed
  2 H H+
  3* H L













Patient with presence of bone marrow involvement.
H = high-dosing regimen (15 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 75 cGy with 131I-tositumomab); H+ = increased
high-dosing regimen (above 15 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 75 cGy with 131I-tositumomab); L = low-dosing
regimen (11 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 65 cGy with 131I-tositumomab); L− = reduced low-dosing regimen
(below 11 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 65 cGy with 131I-tositumomab).
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